Evidence map›Paper›PMID 37445984›Full record

ArticleInternational journal of molecular sciences2023

Antibodies Capable of Enhancing SARS-CoV-2 Infection Can Circulate in Patients with Severe COVID-19.

Andrey Matveev, Oleg Pyankov, Yana Khlusevich, Olga Tyazhelkova, Lyudmila Emelyanova, Anna Timofeeva, Andrey Shipovalov, Anton Chechushkov, Natalia Zaitseva, Gleb Kudrov and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Antibody-dependent enhancement of coronaviruses.International journal of biological sciences · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Andrey MatveevInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-6884-6104
Oleg PyankovState Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor, 630559 Koltsovo, Russia.
Yana KhlusevichInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Olga TyazhelkovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Lyudmila EmelyanovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Anna TimofeevaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0002-1270-7164
Andrey ShipovalovState Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor, 630559 Koltsovo, Russia.
Anton ChechushkovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Natalia ZaitsevaLaboratory of Molecular Epidemiology and Biodiversity of Viruses, Research Institute of Virology, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia.
Gleb KudrovState Research Center of Virology and Biotechnology "VECTOR", Rospotrebnadzor, 630559 Koltsovo, Russia.
Gaukhar YusubalievaFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, Russia.ORCID 0000-0003-3056-4889
Saule YussubaliyevaDepartment of General Medical Practice with the Course of Evidence-Based Medicine, Astana Medical University, Nur-Sultan 010000, Kazakhstan.
Oxana ZhukovaFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, Russia.
Vladimir BaklaushevFederal Research and Clinical Center for Specialized Types of Medical Care and Medical Technologies FMBA of Russia, 115682 Moscow, Russia.ORCID 0000-0003-1039-4245
Sergey SedykhFaculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia.ORCID 0000-0003-0882-8171
Galina LifshitsInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.ORCID 0000-0001-9048-7710
Artem TikunovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Nina TikunovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUState Research Center of Virology and Biotechnology VECTOR · RUNovosibirsk State University · RUAstana Medical University · KZEngelhardt Institute of Molecular Biology · RUFederal Medical-Biological Agency · RUFederal Research Center of Fundamental and Translational Medicine · RUResearch Center of Neurology · RU

Funding

Russian Science Foundation Project No. 21-74-00141The Ministry of Education and Science of the Russian Federation Project No. 121031300043-8
6 · The paper itself

Abstract

Antibody-dependent enhancement (ADE) has been shown previously for SARS-CoV-1, MERS-CoV, and SARS-CoV-2 infection in vitro. In this study, the first monoclonal antibody (mAb) that causes ADE in a SARS-CoV-2 in vivo model was identified. mAb RS2 against the SARS-CoV-2 S-protein was developed using hybridoma technology. mAb RS2 demonstrated sub-nanomolar affinity and ability to neutralize SARS-CoV-2 infection in vitro with IC

Indexed as

COVID-19Middle East Respiratory Syndrome CoronavirusAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralSARS-CoV-2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralADEantibody-dependent enhancementCOVID-19monoclonal antibodySARS-CoV-2virus neutralizing antibody

Identifiers

PMID37445984
PMCPMC10341398
OpenAlexW4382656053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.